Accenture stock falls as RBC Capital lowers price target on mixed guidance

Accenture (ACN) shares fell after RBC Capital lowered its price target to $285 from $372, citing "mixed" Q4 FY25 results and FY26 guidance, which includes 100-150 basis points of headwinds from the U.S. Federal business. Despite the stock trading near its 52-week low and being down 33% year-to-date, the company reported Q4 revenue and EPS that slightly beat estimates, a 6% increase in new bookings, and robust 80% growth in generative AI bookings exceeding $1.8 billion, with InvestingPro projecting 6% FY26 revenue growth. This divergence in performance metrics and forward guidance has led to varied analyst reactions, with several firms adjusting targets lower due to outlook concerns while others maintain higher targets based on strong execution.

Analysis

Accenture (ACN) stock is under pressure, trading near its 52-week low after a nearly 33% year-to-date decline, exacerbated by RBC Capital's price target reduction to $285 from $372. This revision was prompted by what RBC termed "mixed" fourth-quarter fiscal 2025 results and initial fiscal 2026 guidance, which includes a notable 100-150 basis point headwind from the U.S. Federal business. Despite this, Accenture's recent performance metrics present a more nuanced picture. The company slightly surpassed analyst estimates with Q4 revenue of $17.6 billion and EPS of $3.03, and demonstrated a return to growth with new bookings rising 6% year-over-year to $21.3 billion. A significant bright spot is the rapid expansion in generative AI, where bookings have exceeded $1.8 billion, marking an 80% increase from the previous year and signaling a transition from proof-of-concept to production. This fundamental strength has created a divergence in analyst sentiment; while firms like TD Cowen, Guggenheim, and Evercore ISI have lowered targets to the $280-$295 range citing mixed outlooks and margin concerns, Goldman Sachs and UBS maintain higher targets of $330 and $315 respectively, pointing to strong execution.

Key Decisions for Investors

• Given the stock's 33% year-to-date decline, investors may consider the current valuation an entry point, weighing the near-term guidance headwinds against the robust 80% growth in generative AI bookings.
• It is crucial to monitor the performance of the U.S. Federal business, as management guidance indicates the low-end forecast assumes further deterioration in this segment, representing a key risk factor.
• Investors should watch for commentary on the conversion of the $1.8 billion in AI bookings into revenue, as this will be a primary catalyst to offset discretionary spending weakness and drive a potential stock re-rating.
• The planned increase in capital expenditures to approximately $1 billion in FY26 should be treated as a long-term investment, but its impact on near-term free cash flow needs to be factored into valuation models.